Purpose: Gliomas, particularly low-grade gliomas (LGGs), are highly epileptogenic. Seizure is the most common presenting sign of LGG patients and significantly decreases their quality of life. Accordingly, there is a need for a better understanding of the mechanisms and risk factors of glioma-related epilepsy. The current study aimed to perform a comprehensive meta-analysis to investigate the correlation of isocitrate-dehydrogenase 1 (IDH1), an important molecular biomarker for glioma classification and prognosis, to preoperative seizure incidence in LGG. Methods: PUBMED, EMBASE, and Web of Science databases were searched for relevant studies. The odds ratio (OR) and corresponding 95% confidence interval (CI) were used as the primary measures to assess the correlation between IDH1 mutation and preoperative seizure incidence. Results: A total of 722 LGG patients, including 555 patients with IDH1 mutation and 167 patients with wild-type IDH1 were enrolled in the current meta-analysis. The pooled OR was 2.47 (95% CI 1.70-3.57, Z = 4.78, p < 0.01). No significant heterogeneity was observed among all included studies and no publication bias was identified. Conclusion: The current meta-analysis identified that IDH1 mutation was correlated to a higher preoperative seizure incidence in LGG. This result would generate impetus for research on the mechanisms behind this correlation, and provide a new idea for the individualized treatment of gliomarelated epilepsy.
Introduction
Glioma, which accounts for approximately 81% of primary malignant brain tumors, is the most frequent type of primary central nervous system neoplasms in adults [1] . It is a kind of neuronal malignancy which originates from astrocytes, oligodendrocytes or rarely a mix of the two, and can be typically divided into four grades based on pathologic evaluation according to the World Health Organization (WHO) classification [2, 3] . To date, neurosurgeons and clinical oncologists have been concentrating on understanding glioma better, and with their efforts, significant progress has been made over recent decades in our understanding of glioma tumorigenesis and biology. However, many issues remain to be investigated. For instance, glioma-related epilepsy is still poorly understood.
Gliomas, particularly low-grade gliomas ( LGGs, including astrocytomas, oligodendrogliomas, and few molecularly "true" oligoastrocytomas, WHO grade II), are highly epileptogenic. Seizure is the most common presenting sign of LGG and occurs in 65-90% of cases [4, 5] . For most patients, seizure presents as an initial symptom and leads to the tumor diagnosis, while some others may experience their first seizure later during the course of the disease. The presence of seizure carries both heavy financial and emotional burden on patients, and significantly decreases their quality of life [6] . Currently, the conventional treatment of glioma-related epilepsy is combined by antiepileptic drugs and antitumor therapies (maximal safe resection followed by adjuvant radio-chemo-therapy). However, 50% of the patients show drugresistant preoperatively and refractory epilepsy still exists in 15%-35% of cases despite conventional treatment [7] . Accordingly, there is a need for a better understanding of the mechanisms and risk factors of glioma-related epilepsy to optimize the treatment and improve patient quality of life.
Glioma is a disease associated with profound genomic alterations, several genetic alterations have been demonstrated to contribute to epileptogenesis and/or identified as risk factors of glioma-related epilepsy [8] [9] [10] . Isocitrate-dehydrogenase 1 (IDH1) is a key rate limiting enzyme in tricarboxylic acid cycle. IDH1 mutation is an early event in gliomagenesis, and plays a crucial role in the new WHO classification for glioma, which is based on genotype and phenotype [3, 11] . Several previous researches have explored the association between IDH1 mutation and preoperative seizure in LGG, however, most of those studies are limited by small sample size and the results are inconsistent. For instance, Stockhammer et al. and Liang et al. revealed a significant correlation between IDH1 mutation and preoperative seizure in LGG [12, 13] , while Mulligan et al. failed to find such association [14] . In the current study, we performed a comprehensive metaanalysis to investigate the relationship between IDH1 mutation and preoperative seizure incidence in LGG, and finally drew a definite conclusion on this issue. Additionally, the heterogeneity and publication bias were also assessed.
Methods

Search strategy and selection criteria
The current systematic review and meta-analysis was conducted following the Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data (PRISMA-IPD) guidelines [15] . PUBMED, EMBASE, and Web of Science databases were searched for relevant studies published from their inception to 16th July 2017. The search strategy was a combination of the following MeSH terms: "seizure" or "epilepsy", "glioma" or "astrocytoma" or "oligodendroglioma" or "oligoastrocytoma" and "isocitrate dehydrogenase" or "IDH". All titles and abstracts retrieved by searching were downloaded and stored using Endnote X7 software (Thomson Reuters, New York, NY, USA). Subsequently, duplicates were removed, and the remaining studies were further screened in two steps, first, abstracts returned by the search were examined, studies which met any of the following criteria were excluded:
Exclusion Criteria: 1) systematic reviews; 2) guidelines or classifications; 3) meeting abstracts or abstract-only studies; 4) case reports or small case series (LGG cases <5); 5) studies only refer to the high-grade glioma; 6) studies only refer to other neuronal tumors (such as gangliogliomas and dysembryoplastic neuroepithelial tumors); 7) studies of animal experiments or in vitro experiments; 8) other irrelevant studies.
Next, full-text papers of potentially relevant studies were obtained and examined. Studies which fulfilled the following inclusion criteria were finally included in the current metaanalysis: 1) reports of patients with LGGs causing seizure preoperatively, no matter whether the reports contain the information about high-grade glioma; 2) preoperative seizure incidence could be stratified into two groups (IDH1 mutant group versus IDH1 wild-type group); 3) the odds ratio (OR) and corresponding 95% confidence interval (CI) were provided, or could be calculated. For some studies, sufficient data for assessment were not available, we would contact the authors of those studies to get the original data. 
Data extraction and management
Literature search was performed by a separate author, then articles were reviewed and screened independently by two authors. Subsequently, the same two authors independently extracted data for the selected eligible studies, a standardized data collection form was used. Any disagreement would be resolved through additional discussion with the third author.
Quality assessment
The quality of each study finally included was assessed according to the Newcastle-Ottawa Scale (NOS, http://www.ohri. ca/programs/clinical_epidemiology/oxford.htm), a 9-star system of quality assessment for non-randomized studies. The number of stars reflects the quality of a non-randomized study. The overall strength of evidence was evaluated with GRADE criteria in GRADE profiler (version 3.6.1, McMaster University, Hamilton, Ontario, Canada) [16, 17] . The GRADE system classifies the quality of evidence into high, moderate, low, or very low based on five factors: risk of bias, inconsistency, indirectness, imprecision and publication bias.
Data analysis
The OR and corresponding 95% CI were used as the primary measures to assess the correlation between IDH1 mutation and preoperative seizure incidence in LGG. Meta-analysis was done by the generic inverse variance facility of Review Manager software (RevMan, version 5.3, Nordic Cochrane Centre, Cochrane Collaboration, Copenhagen, Denmark). Cochran's Q test and I 2 statistic
were performed by Revman, meanwhile H statistic and Galbraith plot were performed using Stata software (version 12.0, Stata corporation, College station, Texas, USA) to evaluate the betweenstudy heterogeneity. In the presence of significant heterogeneity (I 2 > 50%; a p-value <0.10 for Cochran's Q test and I 2 > 25%; H > 1.5 or 1.5 ! H ! 1.2 and the corresponding 95% CI does not include 1), data would be pooled using a random-effects model, otherwise, a fixed-effect model would be used. A funnel plot was generated by Revman to evaluate the publication bias, a two-tailed p-value <0.05 was considered statistically significant. Moreover, both Egger's linear regression test and Begg's adjusted-rank correlation test were performed by Stata to assess the publication bias (a pvalue <0.05 was considered representative of significant statistical publication bias).
Results
Studies
55 references from PUBMED, 150 from EMBASE and 40 from Web of Science were identified through a comprehensive literature search. After the removal of duplicates, 158 abstracts were reviewed and screened. 14 studies were selected for full-text assessment, and 6 studies met the inclusion criteria [12] [13] [14] [18] [19] [20] . Among the 8 excluded full-text articles, 4 of them didn't have sufficient data for analysis. We contacted the authors of these 4 studies and obtained the original data from 2 of them [21, 22] . Fig. 1 presents the flowchart.
Study characteristics and quality of evidence
The 8 cohort studies were published between 2012 and 2017. Among those studies, 3 were done in China, 2 in Germany, and one each in USA, Australia, and Ireland. One of them was a prospective cohort study, and the other 7 studies were retrospective cohort studies. The characteristics of the included studies are exhibited in Table 1 .
The quality evaluation of each included study was performed according to NOS ( Table 1 ). The overall strength of evidence was evaluated with GRADE criteria and was rated as moderate.
Data analysis
A total of 722 patients with histologically confirmed LGGs were enrolled in the meta-analysis, including 555 (76.9%) patients with IDH1 mutation and 167 (23.1%) patients with wild-type IDH1, preoperative seizure was observed in 501 (72.3%) patients (Table 2) . IDH1 mutation was correlated to a significantly higher incidence of preoperative seizure than wild-type IDH1 in LGG (pooled OR 2.47, 95% CI 1.70-3.57, Z = 4.78, p < 0.001; Fig. 2 ). No significant heterogeneity was found between the studies (I 2 = 0%, p = 0.450 for Cochran's Q test, H = 1). The Galbraith plot is shown in Fig. 3 . The funnel plot is shown in Fig. 4 and no significant publication bias is found. Additionally, the Egger's linear regression test (t = 1.31, p = 0.240, 95% CI À1.09 to 3.60; Fig. 5 ) and the Begg's adjusted-rank correlation test (z = 0.87, p = 0.386; Fig. 6 ) also suggested that there was no significant publication bias.
Discussion
The current meta-analysis determined the correlation of IDH1 mutation to a higher preoperative seizure incidence in LGG, with a pooled OR of 2.47 (95% CI 1.70-3.57). No significant heterogeneity was observed among all included studies and no publication bias was identified, which suggested that the results were stable and statistically robust.
In recent decades, significant progress has been made through genomic analysis in the molecular understanding of glioma. A variety of novel diagnostic, predictive, and prognostic molecular alterations, such as IDH1 mutation, 1p19q co-deletion, telomerase reverse transcriptase (TERT) promoter mutation, O6-methylguanine DNA methyltransferase (MGMT) promoter methylation, phosphatase and tensin homolog (PTEN) mutation and epithelial growth factor receptor (EGFR) amplification, have been identified [23, 24] . Among them, IDH1 mutation is undoubtedly one of the most important molecular biomarkers for glioma classification and prognosis. IDH1 mutation was first discovered through an integrated genomic analysis of glioblastoma (GBM, WHO grade IV) [25] . The most common alteration of IDH1 is R132H (c.395G > A), which comprises over 80 percent of IDH1 mutations [26] . In subsequent studies, IDH1 mutation was identified in the majority of LGGs, anaplastic gliomas (WHO grade III) and secondary GBMs [11, 27, 28] . Those studies revealed an unexpected role for IDH1 mutation in glioma tumorigenesis and progression, and generated a great impetus for research on it. Additionally, numerous studies have demonstrated that patients with IDH1 mutation exhibit different clinical features from patients with wild-type IDH1. For instance, some studies showed that IDH1 mutation was associated with a younger age of diagnosis in glioma [11, 29] . Moreover, glioma patients with IDH1 mutation often have a significantly better prognosis [30, 31] . Table 2 The correlation between IDH1 mutation and preoperative seizure incidence in LGG. LGG, low-grade glioma. Fig. 2 . The forest plot shows that IDH1 mutation is correlated to a significantly higher incidence of preoperative seizure than wild-type IDH1 in LGG. IDH1, isocitrate-dehydrogenase 1;
LGG, low-grade glioma. The relationship between IDH1 mutation and preoperative seizure has been widely investigated in LGG [12] [13] [14] [18] [19] [20] [21] [22] 32, 33] , on the contrary, it has been rarely explored in anaplastic glioma and GBM. Chen et al. reported a significant correlation of IDH1 mutation to preoperative seizure in gliomas, independent of WHO grade [22] . Recently, Toledo et al. also demonstrated such association between IDH1 mutation and preoperative seizure in GBM [34] . However, Yang et al. investigated the correlation of preoperative seizure with clinicopathological features in 198 Chinese patients with anaplastic gliomas, and identified that there was no significant association between IDH1 mutation and preoperative seizure [35] . The results of relevant studies remain inconsistent. Furthermore, because of the limited number of relevant studies, the association between IDH1 mutation and preoperative seizure in high-grade glioma cannot be determined by meta-analysis at present.
The mechanisms behind the correlation between IDH1 mutation and glioma-related epilepsy have been investigated and partly elucidated. The release of (D)-2-hydroxyglutarate (D2HG) product into the tumor microenvironment by IDH1 mutant glioma cells is supposed to be a major mechanism. Dang et al first reported that mutant IDH1 could produce D2HG from a-ketoglutarate in 2009, and they suggested that D2HG might play a causative role in the genesis of glioma [36] . Additionally, subsequent studies demonstrated that D2HG also played an important role in the epileptogenesis of glioma-related epilepsy. This is mainly due to its structural features: the D2HG is structurally similar to glutamate, which is the most widespread excitatory neurotransmitter in our central nervous system. IDH1 mutant glioma cells could release D2HG into the tumor microenvironment, then D2HG could increase neuronal activity by mimicking the activity of glutamate, disrupt the excitation-inhibition balance, and finally lead to glioma-related epilepsy [37, 38] . Chen et al. also reported that exogenous D2HG could increase the firing rate of cultured rat cortical neurons [22] . Additionally, there may be other yet unknown mechanisms which need further investigation.
To date, a series of IDH1 inhibitors have been identified through high-throughput screening. A recent study showed that a selective R132H-IDH1 inhibitor, AGI-5198, could effectively decrease D2HG production of glioma cells and delayed tumor growth [39] . From the discovery, we can speculate that IDH1 inhibitors could be used for seizure control in patients with IDH1 mutant gliomas. This may provide a new idea for the individualized treatment of gliomarelated epilepsy.
The current study also had some limitations. Although we didn't find any statistically significant heterogeneity or publication bias, 7 of the studies included in the current meta-analysis were retrospective, moreover, none of the studies were randomized. Additional high-quality studies are needed for further verification.
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